St. Louis, MO, United States of America

Makoto Ishikawa

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Washington University. Active years: 2022-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Makoto Ishikawa. Retrieved from https://idiyas.com/inventor/makoto-ishikawa-ddlql2xe

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

% Patents Active = 50.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2022-2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Makoto Ishikawa

Introduction

Makoto Ishikawa is a notable inventor based in St. Louis, MO. He has made significant contributions to the field of neurodegenerative research. His work focuses on neurosteroids and their potential applications in treating various neurodegenerative conditions.

Latest Patents

Ishikawa holds a patent titled "Neurosteroids and enantiomers thereof for the prevention and treatment of neurodegenerative conditions." This patent describes a composition aimed at preventing or treating neurodegenerative conditions. The composition includes a neurosteroid, a synthetic enantiomer of a neurosteroid, or a combination of both.

Career Highlights

Ishikawa is affiliated with Washington University, where he conducts his research. His work has garnered attention for its innovative approach to addressing neurodegenerative diseases. He has been instrumental in advancing the understanding of neurosteroids and their therapeutic potential.

Collaborations

Ishikawa has collaborated with esteemed colleagues such as Douglas F. Covey and Charles F. Zorumski. These partnerships have enriched his research and contributed to the development of new therapeutic strategies.

Conclusion

Makoto Ishikawa's contributions to the field of neurodegenerative research highlight the importance of innovation in medicine. His work continues to pave the way for new treatments that could significantly impact patient care.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…